Loading…
Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine
Highlights ► No direct evidence exists for effectiveness of the new serotypes covered by PCV13. ► Efficacy was presumed via a putative serological correlate of protection. ► One dose of PCV13 showed 70% efficacy against IPD caused by new serotypes. ► Protection also demonstrated against individual s...
Saved in:
| Published in: | Vaccine 2011-11, Vol.29 (49), p.9127-9131 |
|---|---|
| Main Authors: | , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c533t-13a1a43951db2ec0eac5a1a655c60240a3b364c94104e400319473b8a69f31bd3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c533t-13a1a43951db2ec0eac5a1a655c60240a3b364c94104e400319473b8a69f31bd3 |
| container_end_page | 9131 |
| container_issue | 49 |
| container_start_page | 9127 |
| container_title | Vaccine |
| container_volume | 29 |
| creator | Miller, Elizabeth Andrews, Nicholas J Waight, Pauline A Slack, Mary P.E George, Robert C |
| description | Highlights ► No direct evidence exists for effectiveness of the new serotypes covered by PCV13. ► Efficacy was presumed via a putative serological correlate of protection. ► One dose of PCV13 showed 70% efficacy against IPD caused by new serotypes. ► Protection also demonstrated against individual serotypes for 7F and 19A. ► 50% less IPD in children |
| doi_str_mv | 10.1016/j.vaccine.2011.09.112 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_904484358</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0264410X11015544</els_id><sourcerecordid>3272416591</sourcerecordid><originalsourceid>FETCH-LOGICAL-c533t-13a1a43951db2ec0eac5a1a655c60240a3b364c94104e400319473b8a69f31bd3</originalsourceid><addsrcrecordid>eNqNkl2L1TAQhoso7nH1J6gFEa9aM_lqe6PIsn7AguC64F1I0-ma2pOcTdoj59-beqoLe6PkIjA88-bNvJNlT4GUQEC-Hsq9NsY6LCkBKElTAtB72QbqihVUQH0_2xAqecGBfDvJHsU4EEIEg-ZhdkKhqRmTsMm-nPc9msnu0WGMue_z6TvmDn_mEYOfDjuMuXW_i8CKvR7RTfnO4bz1xhujx9x4N8zXesJ8NfQ4e9DrMeKT9T7Nrt6ffz37WFx8_vDp7N1FYQRjUwFMg-asEdC1FA1BbUSqSCGMJJQTzVomuWmSf46ckOScV6yttWx6Bm3HTrNXR91d8DczxkltbTQ4jtqhn6NqCOc1Z6L-DxIkpzVliXxxhxz8HFz6hgIBvK6orBY9caRM8DEG7NUu2K0OBwVELemoQa3DUEs6ijQqpZP6nq3qc7vF7m_XnzgS8HIFdEyz7YN2xsZbjlciHZm450eu117p65CYq8v0kiAEOOVssfj2SGBKYG8xqGgsOoOdDSlv1Xn7T7Nv7iiY0TqbbP3AA8bbuahIFVGXy7ItuwZJUwjO2S9K_svN</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1514872678</pqid></control><display><type>article</type><title>Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine</title><source>ScienceDirect Freedom Collection 2022-2024</source><creator>Miller, Elizabeth ; Andrews, Nicholas J ; Waight, Pauline A ; Slack, Mary P.E ; George, Robert C</creator><creatorcontrib>Miller, Elizabeth ; Andrews, Nicholas J ; Waight, Pauline A ; Slack, Mary P.E ; George, Robert C</creatorcontrib><description>Highlights ► No direct evidence exists for effectiveness of the new serotypes covered by PCV13. ► Efficacy was presumed via a putative serological correlate of protection. ► One dose of PCV13 showed 70% efficacy against IPD caused by new serotypes. ► Protection also demonstrated against individual serotypes for 7F and 19A. ► 50% less IPD in children <2 years from one of the new serotypes since introduction.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2011.09.112</identifier><identifier>PMID: 21983361</identifier><identifier>CODEN: VACCDE</identifier><language>eng</language><publisher>Kidlington: Elsevier Ltd</publisher><subject>13-Valent vaccine ; Age ; Allergy and Immunology ; Applied microbiology ; Bacterial diseases ; Bacteriology ; Biological and medical sciences ; children ; confidence interval ; Confidence intervals ; England - epidemiology ; Estimates ; Fundamental and applied biological sciences. Psychology ; Human bacterial diseases ; Humans ; Immunization Programs ; Infant ; Infectious diseases ; Invasive pneumococcal disease ; Laboratories ; Medical sciences ; Microbiology ; Miscellaneous ; Pneumococcal conjugate vaccine ; Pneumococcal Infections - epidemiology ; Pneumococcal Infections - prevention & control ; Pneumococcal Vaccines - administration & dosage ; Pneumococcal Vaccines - immunology ; Population Surveillance ; serotypes ; Serotyping ; Staphylococcal infections, streptococcal infections, pneumococcal infections ; Streptococcus infections ; Streptococcus pneumoniae ; Streptococcus pneumoniae - classification ; Studies ; vaccination ; Vaccination - statistics & numerical data ; Vaccine effectiveness ; Vaccines ; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) ; Vaccines, Conjugate - administration & dosage ; Vaccines, Conjugate - immunology ; Wales - epidemiology</subject><ispartof>Vaccine, 2011-11, Vol.29 (49), p.9127-9131</ispartof><rights>Elsevier Ltd</rights><rights>2011 Elsevier Ltd</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2011 Elsevier Ltd. All rights reserved.</rights><rights>Copyright Elsevier Limited Nov 15, 2011</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c533t-13a1a43951db2ec0eac5a1a655c60240a3b364c94104e400319473b8a69f31bd3</citedby><cites>FETCH-LOGICAL-c533t-13a1a43951db2ec0eac5a1a655c60240a3b364c94104e400319473b8a69f31bd3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24757576$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21983361$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Miller, Elizabeth</creatorcontrib><creatorcontrib>Andrews, Nicholas J</creatorcontrib><creatorcontrib>Waight, Pauline A</creatorcontrib><creatorcontrib>Slack, Mary P.E</creatorcontrib><creatorcontrib>George, Robert C</creatorcontrib><title>Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>Highlights ► No direct evidence exists for effectiveness of the new serotypes covered by PCV13. ► Efficacy was presumed via a putative serological correlate of protection. ► One dose of PCV13 showed 70% efficacy against IPD caused by new serotypes. ► Protection also demonstrated against individual serotypes for 7F and 19A. ► 50% less IPD in children <2 years from one of the new serotypes since introduction.</description><subject>13-Valent vaccine</subject><subject>Age</subject><subject>Allergy and Immunology</subject><subject>Applied microbiology</subject><subject>Bacterial diseases</subject><subject>Bacteriology</subject><subject>Biological and medical sciences</subject><subject>children</subject><subject>confidence interval</subject><subject>Confidence intervals</subject><subject>England - epidemiology</subject><subject>Estimates</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Human bacterial diseases</subject><subject>Humans</subject><subject>Immunization Programs</subject><subject>Infant</subject><subject>Infectious diseases</subject><subject>Invasive pneumococcal disease</subject><subject>Laboratories</subject><subject>Medical sciences</subject><subject>Microbiology</subject><subject>Miscellaneous</subject><subject>Pneumococcal conjugate vaccine</subject><subject>Pneumococcal Infections - epidemiology</subject><subject>Pneumococcal Infections - prevention & control</subject><subject>Pneumococcal Vaccines - administration & dosage</subject><subject>Pneumococcal Vaccines - immunology</subject><subject>Population Surveillance</subject><subject>serotypes</subject><subject>Serotyping</subject><subject>Staphylococcal infections, streptococcal infections, pneumococcal infections</subject><subject>Streptococcus infections</subject><subject>Streptococcus pneumoniae</subject><subject>Streptococcus pneumoniae - classification</subject><subject>Studies</subject><subject>vaccination</subject><subject>Vaccination - statistics & numerical data</subject><subject>Vaccine effectiveness</subject><subject>Vaccines</subject><subject>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</subject><subject>Vaccines, Conjugate - administration & dosage</subject><subject>Vaccines, Conjugate - immunology</subject><subject>Wales - epidemiology</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><recordid>eNqNkl2L1TAQhoso7nH1J6gFEa9aM_lqe6PIsn7AguC64F1I0-ma2pOcTdoj59-beqoLe6PkIjA88-bNvJNlT4GUQEC-Hsq9NsY6LCkBKElTAtB72QbqihVUQH0_2xAqecGBfDvJHsU4EEIEg-ZhdkKhqRmTsMm-nPc9msnu0WGMue_z6TvmDn_mEYOfDjuMuXW_i8CKvR7RTfnO4bz1xhujx9x4N8zXesJ8NfQ4e9DrMeKT9T7Nrt6ffz37WFx8_vDp7N1FYQRjUwFMg-asEdC1FA1BbUSqSCGMJJQTzVomuWmSf46ckOScV6yttWx6Bm3HTrNXR91d8DczxkltbTQ4jtqhn6NqCOc1Z6L-DxIkpzVliXxxhxz8HFz6hgIBvK6orBY9caRM8DEG7NUu2K0OBwVELemoQa3DUEs6ijQqpZP6nq3qc7vF7m_XnzgS8HIFdEyz7YN2xsZbjlciHZm450eu117p65CYq8v0kiAEOOVssfj2SGBKYG8xqGgsOoOdDSlv1Xn7T7Nv7iiY0TqbbP3AA8bbuahIFVGXy7ItuwZJUwjO2S9K_svN</recordid><startdate>20111115</startdate><enddate>20111115</enddate><creator>Miller, Elizabeth</creator><creator>Andrews, Nicholas J</creator><creator>Waight, Pauline A</creator><creator>Slack, Mary P.E</creator><creator>George, Robert C</creator><general>Elsevier Ltd</general><general>Elsevier</general><general>Elsevier Limited</general><scope>FBQ</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20111115</creationdate><title>Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine</title><author>Miller, Elizabeth ; Andrews, Nicholas J ; Waight, Pauline A ; Slack, Mary P.E ; George, Robert C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c533t-13a1a43951db2ec0eac5a1a655c60240a3b364c94104e400319473b8a69f31bd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>13-Valent vaccine</topic><topic>Age</topic><topic>Allergy and Immunology</topic><topic>Applied microbiology</topic><topic>Bacterial diseases</topic><topic>Bacteriology</topic><topic>Biological and medical sciences</topic><topic>children</topic><topic>confidence interval</topic><topic>Confidence intervals</topic><topic>England - epidemiology</topic><topic>Estimates</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Human bacterial diseases</topic><topic>Humans</topic><topic>Immunization Programs</topic><topic>Infant</topic><topic>Infectious diseases</topic><topic>Invasive pneumococcal disease</topic><topic>Laboratories</topic><topic>Medical sciences</topic><topic>Microbiology</topic><topic>Miscellaneous</topic><topic>Pneumococcal conjugate vaccine</topic><topic>Pneumococcal Infections - epidemiology</topic><topic>Pneumococcal Infections - prevention & control</topic><topic>Pneumococcal Vaccines - administration & dosage</topic><topic>Pneumococcal Vaccines - immunology</topic><topic>Population Surveillance</topic><topic>serotypes</topic><topic>Serotyping</topic><topic>Staphylococcal infections, streptococcal infections, pneumococcal infections</topic><topic>Streptococcus infections</topic><topic>Streptococcus pneumoniae</topic><topic>Streptococcus pneumoniae - classification</topic><topic>Studies</topic><topic>vaccination</topic><topic>Vaccination - statistics & numerical data</topic><topic>Vaccine effectiveness</topic><topic>Vaccines</topic><topic>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</topic><topic>Vaccines, Conjugate - administration & dosage</topic><topic>Vaccines, Conjugate - immunology</topic><topic>Wales - epidemiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Miller, Elizabeth</creatorcontrib><creatorcontrib>Andrews, Nicholas J</creatorcontrib><creatorcontrib>Waight, Pauline A</creatorcontrib><creatorcontrib>Slack, Mary P.E</creatorcontrib><creatorcontrib>George, Robert C</creatorcontrib><collection>AGRIS</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>ProQuest Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest Health Management Database</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest research library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Miller, Elizabeth</au><au>Andrews, Nicholas J</au><au>Waight, Pauline A</au><au>Slack, Mary P.E</au><au>George, Robert C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2011-11-15</date><risdate>2011</risdate><volume>29</volume><issue>49</issue><spage>9127</spage><epage>9131</epage><pages>9127-9131</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><coden>VACCDE</coden><abstract>Highlights ► No direct evidence exists for effectiveness of the new serotypes covered by PCV13. ► Efficacy was presumed via a putative serological correlate of protection. ► One dose of PCV13 showed 70% efficacy against IPD caused by new serotypes. ► Protection also demonstrated against individual serotypes for 7F and 19A. ► 50% less IPD in children <2 years from one of the new serotypes since introduction.</abstract><cop>Kidlington</cop><pub>Elsevier Ltd</pub><pmid>21983361</pmid><doi>10.1016/j.vaccine.2011.09.112</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2011-11, Vol.29 (49), p.9127-9131 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_904484358 |
| source | ScienceDirect Freedom Collection 2022-2024 |
| subjects | 13-Valent vaccine Age Allergy and Immunology Applied microbiology Bacterial diseases Bacteriology Biological and medical sciences children confidence interval Confidence intervals England - epidemiology Estimates Fundamental and applied biological sciences. Psychology Human bacterial diseases Humans Immunization Programs Infant Infectious diseases Invasive pneumococcal disease Laboratories Medical sciences Microbiology Miscellaneous Pneumococcal conjugate vaccine Pneumococcal Infections - epidemiology Pneumococcal Infections - prevention & control Pneumococcal Vaccines - administration & dosage Pneumococcal Vaccines - immunology Population Surveillance serotypes Serotyping Staphylococcal infections, streptococcal infections, pneumococcal infections Streptococcus infections Streptococcus pneumoniae Streptococcus pneumoniae - classification Studies vaccination Vaccination - statistics & numerical data Vaccine effectiveness Vaccines Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) Vaccines, Conjugate - administration & dosage Vaccines, Conjugate - immunology Wales - epidemiology |
| title | Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T23%3A45%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effectiveness%20of%20the%20new%20serotypes%20in%20the%2013-valent%20pneumococcal%20conjugate%20vaccine&rft.jtitle=Vaccine&rft.au=Miller,%20Elizabeth&rft.date=2011-11-15&rft.volume=29&rft.issue=49&rft.spage=9127&rft.epage=9131&rft.pages=9127-9131&rft.issn=0264-410X&rft.eissn=1873-2518&rft.coden=VACCDE&rft_id=info:doi/10.1016/j.vaccine.2011.09.112&rft_dat=%3Cproquest_cross%3E3272416591%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c533t-13a1a43951db2ec0eac5a1a655c60240a3b364c94104e400319473b8a69f31bd3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1514872678&rft_id=info:pmid/21983361&rfr_iscdi=true |